2014 CME Symposia - Dinner Symposium B

Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!

Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.

Dinner Symposium B

Thursday · 7:00 - 9:00pm

Novel and Emerging Combinations to Achieve Glycemic Control and Reduce Cardiometabolic Risk:
A Focus on Incretin-Based Therapy and SGLT2 Inhibitors

Supported by an educational grant from AstraZeneca

Symposium Overview

Newer treatment options, including sodium glucose co-transporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, and several fixed-dose combinations are available or are under development, and may change the treatment paradigm for T2DM. These evidence-based therapies have the potential to work synergistically in combination with other available interventions to achieve glycemic control and to reduce overall cardiometabolic risk for individuals with T2DM. This symposium will keep clinicians apprised of new clinical trial data and developments and discuss how to appropriately integrate these newer and emerging therapies into clinical practice.

Learning Objectives

  • Assess the benefits and limitations of currently available antihyperglycemic therapies as well as the most common reasons patients with T2DM fail to achieve target HbA1c goals.
  • Review the mechanisms of action of incretin-based therapy and SGLT2 inhibitors, and discuss the therapeutic advantages of targeting their novel pathways.
  • Provide healthcare providers with current guideline recommendations concerning how to appropriately integrate combination therapies into clinical practice.
  • Analyze the clinical trial data on these new classes of drugs, such as dual or triple combination therapy, in patients with T2DM at various stages of the disease.
  • Help clinicians understand how to improve outcomes in patients with diabetes by selecting appropriate and effective therapies that tighten glycemic control and reduce overall cardiometabolic risk in patients with T2DM.

Preliminary Agenda & Faculty

7:00 - 7:15pm Introductory Remarks Chairperson: George L. Bakris, MD
7:15 - 7:40pm The Role of Incretin Therapies and Effects on Metabolic Homeostasis Presenter: Richard E. Pratley, MD
7:40 - 8:05pm Renal Involvement in the Control of Plasma Glucose Presenter: Mark E. Molitch, MD
8:05 - 8:30pm Current and Novel Approaches to Glycemia Management: A Focus on Combination Therapy Presenter: Sunder Mudaliar, MD
8:30 - 9:00pm Exploring Synergistic Approaches to Improve Glucose Control and CV Risk Factors:
Interactive, Case-Based Scenarios, Panel Discussion and Debate along with Audience Q&A
Moderator: George L. Bakris, MD
Presenters & discussants: Mark E. Molitch, MD; Sunder Mudaliar, MD; Richard E. Pratley, MD

Mark E. Molitch, MD

  • Martha Leland Sherwin Professor of Endocrinology
  • Div. of Endocrinology, Metabolism and Molecular Medicine
  • Northwestern Univ. Feinberg School of Medicine

Sunder Mudaliar, MD

  • Staff Physician and Director Diabetes Clinic
  • VA San Diego Healthcare System
  • Clinical Professor of Medicine
  • University of California, San Diego
  • San Diego, CA

Richard E. Pratley, MD

  • Samuel E. Crockett Chair in Diabetes Research
  • Medical Director, AdventHealth Diabetes Institute
  • Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
  • AdventHealth
  • Orlando, FL

George L. Bakris, MD

  • Professor of Medicine
  • Director, ASH Comprehensive Hypertension Center
  • University of Chicago Medicine
  • Chicago, IL

View Complete Accreditation Details and Program Overview: CMHC Accreditation